Prostate cancer screening for carriers and noncarriers of pathogenic variants of the BRCA1 and BRCA2 genes identified a higher proportion of clinically relevant disease in the carrier groups. Prostate-specific antigen screening should be recommended for carriers of BRCA1 and BRCA2 pathogenic variants.
Prostate cancer screening for carriers and noncarriers of pathogenic variants of the BRCA1 and BRCA2 genes identified a higher proportion of clinically relevant disease in the carrier groups. Prostate-specific antigen screening should be recommended for carriers of BRCA1 and BRCA2 pathogenic variants.